Axid®(nizatidine) Capsules, USP
Nizatidine (USP) is a histamine H2-receptor antagonist.
Axid Oral Solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.
Axid Oral Solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known.
Axid Oral Solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Axid Oral Solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.
In pediatric patients, Axid Oral Solution is indicated for ages 12 years and older. Axid Oral Solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Published Studies Related to Axid (Nizatidine)
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. [2010.04]
BACKGROUND: Systematic assessments of the onset of symptom relief in the treatment of gastroesophageal reflux disease (GERD) are lacking. OBJECTIVE: This work evaluated the time interval until complete symptom relief from heartburn (including both daytime and nighttime heartburn) and acid regurgitation in patients with GERD or endoscopy-negative GERD (NERD) during the first 7 days of treatment with pantoprazole, nizatidine, or ranitidine... CONCLUSION: In this post hoc reanalysis of data from 2 previously published clinical trials, use of pantoprazole 20 mg once daily was associated with effective early relief from heartburn and acid regurgitation among these patients with GERD and NERD; relief occurred as fast as and, in some cases, even faster than that seen with nizatidine or ranitidine.
Multicenter, double-blind, placebo-controlled crossover study to assess the acute
prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients
with gastroesophageal reflux disease. 
disease (GERD)... CONCLUSIONS: Nizatidine CR (150 and 300 mg) significantly enhanced gastric
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis
of two previously published studies comparing pantoprazole 20 mg once daily with
nizatidine or ranitidine 150 mg twice daily. 
first 7 days of treatment with pantoprazole, nizatidine, or ranitidine... CONCLUSION: In this post hoc reanalysis of data from 2 previously published
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. [2006.12]
CONCLUSIONS: The concomitant use of olanzapine with nizatidine was not effective in controlling weight gain in patients who had previously gained weight during treatment with olanzapine when compared to placebo.
Pharmacokinetics of ranitidine and nizatidine in very elderly patients. [2005.05]
This study was undertaken to examine whether the pharmacokinetic profiles of ranitidine and nizatidine, the H2 antagonists, differed with repeated doses in very elderly patients (>80 years old). Ranitidine (150 mg) or nizatidine (150 mg) was given twice daily in 10 very elderly female patients for 14 days...
Clinical Trials Related to Axid (Nizatidine)
Drug-Drug Interaction Study With Metformin and Nizatidine [Not yet recruiting]
This study will address the following question: Does nizatidine affect the pharmacokinetics
of metformin in healthy volunteers? Recent studies in the Giacomini laboratory have
indicated that nizatidine may block metformin elimination from the kidney by inhibiting
organic cation transporter efflux of metformin. The investigators hypothesize that the
co-administration of metformin and nizatidine will reduce the renal clearance (CLR) of
metformin leading to increased plasma concentrations and potential risk for toxicities.
Knowledge of the pharmacokinetic interaction profile of metformin with organic transporter
inhibitors, such as nizatidine, is important to help develop safer more effective drug
therapy with reduced side effects.
Safety and Efficacy Study of Axid Use in Infants Suffering From GERD [Active, not recruiting]
Weight Gain Management in Patients With Schizophrenia [Completed]
Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with
schizophrenia who have been under treatment with olanzapine for at least two months and
evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent
adverse events, changes in vital signs, laboratory results and extrapyramidal effects.
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects [Recruiting]
To assess if oral nizatidine or lisinopril alone and in combination will increase heme
oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy
Page last updated: 2013-02-10